No open-market selling at Latigo Biotherapeutics, Inc. in the past year, which is unusual. Instead two insiders picked up about $5 million worth of LTGO.
Biggest single buyer: Foresite Capital Fund VI LP, 10% Owner, with roughly $2.5 million.
Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Foresite Capital Fund VI LP | 10% Owner | Buy | 140,000 | $18.00 | $2.5M | SEC |
| Aug 10, 2026 | Tananbaum James B. | Director | Buy | 140,000 | $18.00 | $2.5M | SEC |
In the last 12 months Latigo Biotherapeutics, Inc. insiders made open-market purchases worth about $5 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in LTGO was filed on 2026-08-10.
No congressional trades in LTGO were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).